Tech to Replace Animal Testing Is Almost Ready. Scientists Are Not

IEEE Spectrum reports on the shift from animal testing to NAMs such as organs-on-a-chip and organoids. The FDA has already demanded such data instead of animal results, but validation, training and cultural change remain the main obstacles.

• The lung-on-a-chip was built at Harvard's Wyss Institute in 2010 and has been cited nearly 5,400 times
• The FDA denied a company a clinical trial, demanding organ-on-a-chip data instead of animal data
• About 92% of drugs entering U.S. clinical trials never reach the market
• Adopting NAMs requires policy, training and cultural change, not just technology